


**AMENDMENTS TO THE CLAIMS**

Amend the claims as follows:

Claims 1-122. (cancelled)

123. (Previously Presented) A compound of the formula:



wherein:

$R^N$  is independently  $C_{1-7}$ alkyl;

$X^1$  is independently -I, -Br, or -Cl;

$X^2$  is independently -I, -Br, or -Cl;

the group  $-N(CH_2CH_2X^1)(CH_2CH_2X^2)$  is independently attached at the 2-position or at the 4-position;

each  $R^G$  is independently -H or an ester substituent;

$n$  is independently an integer from 0 to 4;

each  $R^P$ , if present, is independently a phenyl substituent;

$m$  is independently an integer from 0 to 4;

each  $R^M$ , if present, is independently a mustard substituent;

and pharmaceutically acceptable salts, solvates, amides, and esters thereof.

124. (Previously Presented) A compound according to claim 123, wherein R<sup>N</sup> is independently unsubstituted aliphatic C<sub>1-7</sub>alkyl.

125. (Previously Presented) A compound according to claim 123, wherein R<sup>N</sup> is independently unsubstituted aliphatic C<sub>1-4</sub>alkyl.

126. (Previously Presented) A compound according to claim 123, wherein R<sup>N</sup> is independently -Me, -Et, -nPr, -iPr, -allyl, -nBu, -sBu, -iBu, or -tBu.

127. (Previously Presented) A compound according to claim 123, wherein R<sup>N</sup> is independently -Me or -Et.

128. (Previously Presented) A compound according to claim 123, wherein R<sup>N</sup> is independently -Me.

129. (Previously Presented) A compound according to claim 123, wherein each of X<sup>1</sup> and X<sup>2</sup> is independently -I.

130. (Previously Presented) A compound according to claim 123, wherein each of X<sup>1</sup> and X<sup>2</sup> is independently -Br.

131. (Previously Presented) A compound according to claim 123, wherein each of X<sup>1</sup> and X<sup>2</sup> is independently -Cl.

132. (Previously Presented) A compound according to claim 123, wherein  $R^N$  is independently  $C_{1-4}$ alkyl; and, each X is independently -Cl, -Br or -I.

133. (Previously Presented) A compound according to claim 123, wherein  $R^N$  is independently -Me; and, each X is independently -Cl, -Br or -I.

134. (Previously Presented) A compound according to claim 123, wherein  $R^N$  is independently  $C_{1-4}$ alkyl; and, each X is independently -I.

135. (Previously Presented) A compound according to claim 123, wherein  $R^N$  is independently -Et or -Me; and, each X is independently -I.

136. (Previously Presented) A compound according to claim 123, wherein  $R^N$  is independently -Me; and, each X is independently -I.

137. (Previously Presented) A compound according to claim 123, wherein the group  $-N(CH_2CH_2X^1)(CH_2CH_2X^2)$  is independently attached at the 4-position.

138. (Previously Presented) A compound according to claim 123, wherein  
 $R^N$  is independently  $C_{1-4}$ alkyl;  
each X is independently -Cl, -Br or -I; and,  
the group  $-N(CH_2CH_2X)_2$  is independently attached at the 4-position.

139. (Previously Presented) A compound according to claim 123, wherein  
 $R^N$  is independently -Me;  
each X is independently -Cl, -Br or -I; and,  
the group  $-N(CH_2CH_2X)_2$  is independently attached at the 4-position.

140. (Previously Presented) A compound according to claim 123, wherein  
 $R^N$  is independently  $C_{1-4}$ alkyl;  
each X is independently -I; and,  
the group  $-N(CH_2CH_2X)_2$  is independently attached at the 4-position.

141. (Previously Presented) A compound according to claim 123, wherein  
 $R^N$  is independently -Et or -Me;  
each X is independently -I; and,  
the group  $-N(CH_2CH_2X)_2$  is independently attached at the 4-position.

142. (Previously Presented) A compound according to claim 123, wherein

$R^N$  is independently -Me;

each X is independently -I; and,

the group  $-N(CH_2CH_2X)_2$  is independently attached at the 4-position.

143. (Previously Presented) A compound according to claim 123, wherein n is 0, 1, or 2.

144. (Previously Presented) A compound according to claim 138, wherein n is 0.

145. (Previously Presented) A compound according to claim 123, wherein each  $R^P$ , if present, is independently halo,  $C_{1-4}$ alkyl, nitro, or cyano.

146. (Previously Presented) A compound according to claim 123, wherein each  $R^P$ , if present, is independently:

-F, -Cl, -Br, -I, -Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu, -NO<sub>2</sub>, or -CN.

147. (Previously Presented) A compound according to claim 123, wherein each  $R^P$ , if present, is independently -F, -Cl, -Br, or -I.

148. (Previously Presented) A compound according to claim 123, wherein m is 0, 1, or 2.

149. (Previously Presented) A compound according to claim 138, wherein m is 0.

150. (Previously Presented) A compound according to claim 144, wherein m is 0.

151. (Previously Presented) A compound according to claim 123, wherein each R<sup>M</sup>, if present, is independently selected from: C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkoxy; amino; halo; C<sub>1-4</sub>alkylthio; acyl; ester; amido; cyano; nitro; and, C<sub>5-6</sub>aryl.

152. (Previously Presented) A compound according to claim 123, wherein each R<sup>M</sup>, if present, is independently selected from:

-Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu;

-CF<sub>3</sub>, -CH<sub>2</sub>F, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>F; -CF<sub>2</sub>CF<sub>3</sub>;

-OMe, -OEt, -O-nPr, -O-iPr, -O-nBu, -O-sBu, -O-iBu, -O-tBu;

-OCF<sub>3</sub>, -OCH<sub>2</sub>F, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>F; -OCF<sub>2</sub>CF<sub>3</sub>;

-NH<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, -N(nPr)<sub>2</sub>, -N(iPr)<sub>2</sub>,

-F, -Cl, -Br, -I;

-SMe, -SEt;

-C(=O)Me;

-C(=O)OMe, -C(=O)OEt;

-CONH<sub>2</sub>, -CONHMe;

-CN;

-NO<sub>2</sub>; and,

-Ph.

153. (Previously Presented) A compound according to claim 123, wherein each  $R^M$ , if present, is independently selected from:

-Me, -Et, -CF<sub>3</sub>, -OMe, -OEt, -NH<sub>2</sub>, and -NMe<sub>2</sub>.

154. (Previously Presented) A compound according to claim 123, wherein each  $R^G$  is independently -H.

155. (Previously Presented) A compound according to claim 123, wherein each  $R^G$  is independently -H, unsubstituted C<sub>1-7</sub>alkyl, substituted C<sub>1-7</sub>alkyl, or silyl.

156. (Previously Presented) A compound according to claim 123, wherein each  $R^G$  is independently -H; unsubstituted C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkyl substituted with one or more groups selected from optionally substituted C<sub>5-20</sub>aryl, C<sub>1-7</sub>alkoxy, C<sub>1-7</sub>alkylthio, and acyloxy; or -SiR<sup>S</sup><sub>3</sub>, wherein each R<sup>S</sup> is independently -H or C<sub>1-4</sub>alkyl.


157. (Previously Presented) A compound according to claim 123, wherein each  $R^G$  is independently -H; -Me; -Et; -nPr; -iPr; -allyl; -nBu; -sBu; -iBu; -tBu; C<sub>1-4</sub>alkyl substituted with one or more groups selected from optionally substituted phenyl, methoxy, methylthio, acetoxy, and benzoyloxy; -Si(Me)<sub>3</sub>; -Si(Et)<sub>3</sub>; -Si(iPr)<sub>3</sub>; -Si(tBu)(CH<sub>3</sub>)<sub>2</sub>; or -Si(tBu)<sub>3</sub>.

158. (Previously Presented) A compound according to claim 123, wherein each  $R^G$  is independently (1) t-butyl, (2) allyl, (3) tri-isopropylsilyl, (4) acetoxymethyl, (5) methoxymethyl, (6) methylthiomethyl, (7) p-methoxyphenylmethyl, (8) bis(o-nitrophenyl)methyl, (9) benzyl, or (10) diphenylmethyl.

159. (Previously Presented) A compound according to claim 123, wherein each  $R^G$  is independently (1) t-butyl, (2) allyl, or (3) tri-isopropylsilyl.


160. (Previously Presented) A compound according to claim 123, wherein each  $R^G$  is independently (1) allyl.

161. (Previously Presented) A compound selected from compounds of the following formula (P-1), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:






162. (Previously Presented) A compound selected from compounds of the following formula (P-2), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:



163. (Previously Presented) A compound selected from compounds of the following formula (P-3), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:



164. (Previously Presented) A composition comprising a compound according to claim 123, and a pharmaceutically acceptable carrier.

165. (Previously Presented) A kit comprising:
- (a) a compound according to claim 123; and
  - (b) instructions for use.
166. (Previously Presented) A kit comprising:
- (a) a compound according to claim 123;
  - (b) an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,
  - (c) instructions for use.
167. (Previously Presented) A kit comprising:
- (a) a compound according to claim 123;
  - (b) a nucleic acid encoding a carboxypeptidase enzyme; and,
  - (c) instructions for use.
168. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo*, comprising contacting the cell with an effective amount of a compound according to claim 123.~~

Claim 169. (Canceled)

170. (Currently Amended) A method of treatment of colon cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123.

171. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these~~, *in vitro* or *in vivo*, comprising contacting the cell with a therapeutically-effective amount of a compound according to claim 123, in the presence of a carboxypeptidase enzyme.

Claim 172. (Canceled)

173. (Currently Amended) A method of treatment of colon cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123, in the presence of a carboxypeptidase enzyme.

174. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these~~, *in vitro* or *in vivo*, comprising:

(i) contacting the cell with an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

Claim 175. (Canceled)

176. (Currently Amended) A method of treatment of colon cancer, comprising administering to a subject in need of treatment:

(i) an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

177. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo*~~, comprising:

(i) contacting the cell with a nucleic acid encoding a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

Claim 178. (Canceled)

179. (Currently Amended) A method of treatment of colon cancer, comprising administering to a subject in need of treatment:

- (i) a nucleic acid encoding a carboxypeptidase enzyme; and,
- (ii) a therapeutically-effective amount of a compound according to claim 123.